Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
295 GBX | 0.00% | -5.75% | -16.31% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.31% | 385M | |
+8.30% | 218B | |
+6.93% | 182B | |
+11.60% | 132B | |
+27.04% | 108B | |
+13.54% | 52.98B | |
-0.62% | 47.59B | |
-0.66% | 39.96B | |
+11.76% | 39.22B | |
+25.88% | 26.94B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- Stifel Nicolaus Adjusts Price Target for MaxCyte tp $16 From $18, Maintains Buy Rating